Back to Authors

Roman, Lynda D.

https://orcid.org/0000-0002-6960-4414

Mayo Clinic

USC Norris Comprehensive Cancer Center

Citations 3

A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Konecny, Gottfried E. , Jänicke, F., Beckmann, Matthias W. , Feisel, Gabriele, Pölcher, Martin , Rody, Achim , Ray-Coquard, Isabelle Laure, Provencher, Diane , Ben‐Baruch, Noa, Cottu, Paul , Chen, Hsiao‐Wang, Dering, Judy, Jacod, Sylvie, Houé, Vincent, Slamon, Dennis J. , Haluska, Paul , Sehouli, Jalid , Roman, Lynda D. , Karlan, Beth Y. , Wang, Chen

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5529-5529

10.1200/jco.2014.32.15_suppl.5529 Get It

Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer
Matsuo, Koji , Mariani, Andrea , Mandelbaum, Rachel S. , Gostout, Bobbie S., Roman, Lynda D. , Machida, Hiroko , Glaser, Gretchen E., Roman, Lynda D , Glaser, Gretchen , Wright, Jason Dennis

Journal of Gynecologic Oncology | May 9, 2018 | Volume: 29 | Issue: 5 | Pages: No page available

10.3802/jgo.2018.29.e69 Get It

Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy
Nouriani, Mory, Bahador, Afshin, Cheng, Joan, Cliby, William A. , Priore, Giuseppe Del, Dodson, Mark K., Duggan, B., Lentz, Scott E. , Penson, Richard T. , Robinson, William R. , Rodriguez, Mildred, Yu, Mimi C., Zempolich, Karen, Dubeau, Louis , Nouriani, Mory, Berek, Jonathan S. , Dennis, S. , Gershenson, David M. , Roman, Lynda D.

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 8 | Pages: 2681-2686

10.1158/1078-0432.ccr-0523-03 Get It

Abstract Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.